Related Experiment Videos

[Morbidity and mortality after heart transplanation]

M J Rebocho1, C Aguiar, J Queiroz e Melo

  • 1Serviço de Cirurgia Cardiotorácica, Hospital de Santa Cruz, Carnaxide, Portugal.

Insights

Heart transplantation offers a valid treatment for end-stage heart failure, with most long-term survivors experiencing good quality of life. Key challenges include managing infection, rejection, and complications from immunosuppression.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Immunology

Background:

  • Heart transplantation is a critical intervention for end-stage heart failure.
  • Evaluating long-term outcomes is essential for refining patient care and management strategies.

Purpose of the Study:

  • To assess the morbidity and mortality rates following heart transplantation.
  • To analyze the causes of death and complications in patients undergoing heart transplantation at Santa Cruz Hospital.

Main Methods:

  • A retrospective analysis of 113 patients who underwent heart transplantation between February 1986 and December 2000.
  • Kaplan-Meier survival analysis was used to calculate survival rates at 12 months, 5 years, and 10 years.
  • Morbidity, causes of mortality, and quality of life (functional and employment status) were evaluated.

Main Results:

  • Actuarial survival rates were 82.2% at 12 months, 64.6% at 5 years, and 45.3% at 10 years, with a maximum survival of 14.7 years.
  • Infections were the leading cause of early mortality, while allograft vasculopathy and malignancy were major causes of late mortality.
  • Common morbidities included infections (35.4%), rejection episodes, tumors, allograft vasculopathy, and significant side effects of chronic immunosuppression such as hypertension (50%) and dyslipidemia (31%).

Conclusions:

  • Cardiac transplantation remains a viable treatment option for end-stage heart failure.
  • Long-term survivors generally achieve a good quality of life, comparable to the general population.
  • Ongoing monitoring for infection, rejection, and immunosuppression-related complications is crucial for optimizing patient outcomes.
Abstract

Related Concept Videos